Intrinsiqs

Is Supernus Pharmaceuticals, Inc. overvalued?

Supernus Pharmaceuticals, Inc. (SUPN) — key valuation metrics and fundamentals.

No verdict
Price
$46.34
Fair value
Current P/E
Normal P/E
Market cap
$2.70B
Dividend yield
Return on equity
Sector
Healthcare

See the full interactive analysis →

Fair value compares SUPN's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 30 Jun 2026.